Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat

被引:83
作者
Gasser, Jurg A. [1 ]
Ingold, Peter [1 ]
Venturiere, Andrea [1 ]
Shen, Victor [2 ]
Green, Jonathan R. [1 ]
机构
[1] Novartis Inst Biomed Res, CH-4002 Basel, Switzerland
[2] Skele Tech, Seattle, WA USA
关键词
osteoporosis; bone loss; bisphosphonate; single dose; zoledronic acid;
D O I
10.1359/JBMR.071207
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current bisphosphonate therapies effectively prevent bone loss in postmenopausal women. We studied the effect of a single intravenous dose of ZOL in ovariectomized rats. Protection from bone loss was dose dependent, lasting for up to 32 weeks, supporting the rationale for an annual intravenous dosing regimen of ZOL for treatment of postmenopausal osteoporosis. Introduction: Once-yearly dosing with zoledronic acid (ZOL) 5 mg can increase BMD and reduce fracture rate in postmenopausal women with low BMD. The primary objective of this study was to determine the duration of bone protective effects of a single dose of ZOL in ovariectomized rats, an animal model of postmenopausal osteopenia. Secondary objectives were to determine the effects on bone turnover and mechanical properties. Materials and Methods: Female Wistar rats (10 per group) received single intravenous doses of ZOL 0.8, 4, 20, 100, or 500 mu g/kg, alendronate 200 mu g/kg, or isotonic saline 4 days before bilateral ovariectomy. Sham-operated controls were pretreated with saline. Mass and density of cancellous and cortical bone (pQCT) were measured at 4-wk intervals for 32 wk. Bone architecture (mu CT), bone formation dynamics (fluorochrome label-based histomorphometry), and biomechanical strength in compression testing were also assessed at 32 wk. Results: Ovariectomy-associated BMD loss was significantly attenuated for 32 wk by ZOL >= 4 mu g/kg for total BMD, ZOL >= 20 mu g/kg for cortical BMD, and ZOL >= 4 mu g/kg for cancellous BMD (p < 0.01 versus ovariectomized controls). Alendronate 200 mu g/kg was of equivalent potency to ZOL 20 mu g/kg. Ovariectomy-associated decreases in trabecular architectural parameters were dose-dependently attenuated by ZOL. Alendronate 200 mu g/kg was equivalent to ZOL 20 mu g/kg. The bone resorption marker TRACP56 indicated transient suppression of elevated osteoclast activity by ZOL relative to OVX-rats even at the lowest dose of 0.8 mu g/kg, whereas at 100-500 mu g/kg, the effect was significant relative to the OVX control for the entire duration of the study of 32 wk. Bone formation parameters were not significantly affected by ZOL 20 mu g/kg but were significantly reduced by ZOL 100-500 mu g/kg. Alendronate 200 mu g/kg was equivalent to ZOL 100 mu g/kg. ZOL produced dose-related improvements in bone strength parameters after ovariectomy. Alendronate 200 mu g/kg was of similar potency to ZOL 20 mu g/kg. Conclusions: The duration and magnitude of the bone-protecting effect of a single intravenous dose of ZOL in ovariectomized rats is dose dependent and lasts for up to 32 wk. Compared with alendronate, ZOL shows 10-fold higher potency in preventing bone loss. These data support the use of an annual intravenous ZOL dosing regimen for the treatment of osteoporosis.
引用
收藏
页码:544 / 551
页数:8
相关论文
共 31 条
[1]  
Adami S, 2002, CLIN EXP RHEUMATOL, V20, P55
[2]  
AMIN D, 1992, J LIPID RES, V33, P1657
[3]   Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys [J].
Binkley, N ;
Kimmel, D ;
Bruner, J ;
Haffa, A ;
Davidowitz, B ;
Meng, C ;
Schaffer, V ;
Green, J .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (11) :1775-1782
[4]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[5]   Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[6]   Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs [J].
Burr, DB ;
Miller, L ;
Grynpas, M ;
Li, JL ;
Boyde, A ;
Mashiba, T ;
Hirano, T ;
Johnston, CC .
BONE, 2003, 33 (06) :960-969
[7]   PROTEIN LIPIDATION IN CELL SIGNALING [J].
CASEY, PJ .
SCIENCE, 1995, 268 (5208) :221-225
[8]   Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate [J].
Durchschlag, Erich ;
Paschalis, Eleftherios P. ;
Zoehrer, Ruth ;
Roschger, Paul ;
Fratzl, Peter ;
Recker, Robert ;
Phipps, Roger ;
Klaushofer, Klaus .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (10) :1581-1590
[9]   Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [J].
Fisher, JE ;
Rogers, MJ ;
Halasy, JM ;
Luckman, SP ;
Hughes, DE ;
Masarachia, PJ ;
Wesolowski, G ;
Russell, RGG ;
Rodan, GA ;
Reszka, AA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :133-138
[10]  
Gasser J.A., 1995, BONE S, V17, P145